Lamivudine Accord

Lamivudine, the active ingredient in Lamivudine Accord, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adults and adolescents. GNH USA supplies Lamivudine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in the management of viral infections that rely on reverse transcription. - Human immunodeficiency virus (HIV) infection: suppresses viral replication and helps maintain immune function. - Chronic hepatitis B infection: reduces viral load and improves liver health.

Lamivudine may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness or weakness. - Diarrhea: loose stools, often self‑limiting. - Insomnia: difficulty falling or staying asleep. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring urgent care. - Hepatotoxicity: significant liver enzyme elevation or failure. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, fever, or eosinophilia. - Anemia: notable reduction in red blood cell count.

Before initiating lamivudine therapy, clinicians should consider several safety factors. - Renal function: assess baseline creatinine and adjust dose if needed. - Hepatic function: monitor liver enzymes regularly. - Pregnancy: evaluate risk‑benefit ratio and discuss with the patient. - Concomitant antiretrovirals: avoid combinations that increase resistance risk. - Adherence: emphasize consistent daily intake to prevent viral resistance. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis when co‑administered. - Stavudine: heightened mitochondrial toxicity leading to peripheral neuropathy. - Zidovudine: additive bone‑marrow suppression, potentially causing anemia.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides): may require dose adjustment of lamivudine. - Alcohol: can exacerbate liver toxicity. - Antacids containing aluminum or magnesium: may affect lamivudine absorption.